Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects

Inclusion Criteria: 1. Healthy male and female subjects aged 18 to 55 years (inclusive) at the time of signing the informed consent form (ICF). 2. Fasting serum LDL-C ≥ 2.6 mmol/L (100 mg/dL) and \< 4.1 mmol/L (158 mg/dL), and fasting triglycerides ≥ 1.1 mmol/L (100 mg/dL) and \< 5.7 mmol/L (500 mg/dL) at screening; no lipid-regulating drugs used within the past 3 months. 3. Body mass index (BMI) from 19.0 to 30.0 kg/m², inclusive, at screening; male subjects must have a body weight ≥ 50.0 kg and female subjects must have a body weight ≥ 45.0 kg. 4. Stable diet and physical-activity habits for 4 weeks prior to screening; no major changes to diet or exercise are planned during the study, and participants will not follow any weight-loss plan. 5. Subjects or their partners have no plans for pregnancy, sperm donation, or egg donation from the time of signing the ICF until at least 6 months after dosing, and agree to use medically-recognized, effective non-pharmacological contraceptive methods throughout the study. 6. Voluntarily participate in the study; able to read, understand, and sign the ICF before study participation; willing to comply with the study protocol and expected to complete the study. Exclusion Criteria: 1. Any infectious disease within 4 weeks prior to screening (as judged by the investigator to affect the subject's ability to participate in the study). 2. Serious trauma or major surgery (requiring general anesthesia) within 6 months prior to screening, or planned major surgery during the study. 3. At screening, any of the following laboratory abnormalities: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or total bilirubin \> 1.5 × ULN; serum creatinine \> 1.2 × ULN; or estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m² (calculated using the CKD-EPI equation, Appendix 4). 4. QTcF ≥ 450 ms (male) or ≥ 470 ms (female) at screening; or clinically-significant abnormalities on the 12-lead electrocardiogram. 5. HbA1c \> ULN. 6. Overall atherosclerotic cardiovascular disease (ASCVD) risk assessed by the investigator as moderate or high risk at screening. 7. Use of any liver-targeted oligonucleotide drug within 1 year prior to screening. 8. Pregnant or lactating female subjects at screening. 9. Difficult venous access, difficult subcutaneous injection, or intolerance to repeated venipuncture; or clinically significant needle phobia or blood phobia history as judged by the investigator. 10. Use of any over-the-counter medications, prescription medications, traditional Chinese medicine, vitamins, or health supplements within 2 weeks prior to screening or within 5 half-lives of any prior medication (whichever is longer). 11. Receipt of any live vaccine, live attenuated vaccine, or vaccines containing live viral components within 3 months prior to screening or planned vaccination during the study. 12. Any other condition judged by the investigator to make the subject unsuitable for participation in this study.